Pazopanib colon targeted liposomal drug delivery for colorectal cancer: high-pressure homogenization process optimization and In-vivo evaluation
By: Lahoti, Swaroop
.
Contributor(s): Mukesh Kumar.
Publisher: Karnataka Association of Pharmaceutical Teachers of India (APTI) 2022Edition: Vol.56(2), Apr-June.Description: 387-395p.Subject(s): PHARMACEUTICSOnline resources: Click here
In:
Indian journal of pharmaceutical education and researchSummary: Background: Pazopanib is second-generation tyrosinekinase inhibitor used in Colorectal
cancer (CRC) which is effective orally. Targeted liposomal drug delivery will reduce the
unwanted side effects of the drug. The application of High-pressure homogenizers for the
preparation of systems like liposomes and lipid dispersions is rising because of its ability
of vesicle disruption. Aim: Major objective of present research work was to optimize
high pressure homogenization process for formulation of colon targeted liposomal
drug delivery system of Pazopanib and its
in-vivo evaluation. To study the influence of
homogenization Pressure and number of cycles on some parameters, such as vesicle size
and polydispersity index (PDI). Materials and Methods: The liposomes were formulated
with HSPC (Hydrogenated Phosphotidylcholin from Soybean) m-PEG DSPE-2000
(Phospolipid) and Cholesterol using Ethanol injection method followed by downsizing
by EmilsiFlex High pressure Homogenizer. Results and Conclusion: The liposomes were
evaluated for entrapment efficiency,
in-vitro drug release, osmolality, particle size, size
distribution, polydispersity index, FEG-SEM and stability studies. Optimization studies
concluded that the optimized formulation with homogenization pressure of 1000, 1500,
2000 psi and number of cycle 9, 6, 6 respectivly gives particle size of 109 nm with PDI
0.998 and desirability 0.975.
In-vivo studies in wrister rats in which carcino genesis was
done using 1,2- dimethylhydrazine (DMH), indicated that Pazopanib liposomes caused
significant tumors growth suppression in terms of tumor volume and weight as compared
to control. Histo-pathological evaluation showed that the animals treated with pazopanib
liposomes had moderate dysplasia where as untreated animals had severe dysplasia.
| Item type | Current location | Call number | Status | Date due | Barcode | Item holds |
|---|---|---|---|---|---|---|
Articles Abstract Database
|
School of Pharmacy Archieval Section | Not for loan | 2022-1422 |
Background: Pazopanib is second-generation tyrosinekinase inhibitor used in Colorectal
cancer (CRC) which is effective orally. Targeted liposomal drug delivery will reduce the
unwanted side effects of the drug. The application of High-pressure homogenizers for the
preparation of systems like liposomes and lipid dispersions is rising because of its ability
of vesicle disruption. Aim: Major objective of present research work was to optimize
high pressure homogenization process for formulation of colon targeted liposomal
drug delivery system of Pazopanib and its
in-vivo evaluation. To study the influence of
homogenization Pressure and number of cycles on some parameters, such as vesicle size
and polydispersity index (PDI). Materials and Methods: The liposomes were formulated
with HSPC (Hydrogenated Phosphotidylcholin from Soybean) m-PEG DSPE-2000
(Phospolipid) and Cholesterol using Ethanol injection method followed by downsizing
by EmilsiFlex High pressure Homogenizer. Results and Conclusion: The liposomes were
evaluated for entrapment efficiency,
in-vitro drug release, osmolality, particle size, size
distribution, polydispersity index, FEG-SEM and stability studies. Optimization studies
concluded that the optimized formulation with homogenization pressure of 1000, 1500,
2000 psi and number of cycle 9, 6, 6 respectivly gives particle size of 109 nm with PDI
0.998 and desirability 0.975.
In-vivo studies in wrister rats in which carcino genesis was
done using 1,2- dimethylhydrazine (DMH), indicated that Pazopanib liposomes caused
significant tumors growth suppression in terms of tumor volume and weight as compared
to control. Histo-pathological evaluation showed that the animals treated with pazopanib
liposomes had moderate dysplasia where as untreated animals had severe dysplasia.
Click on an image to view it in the image viewer
There are no comments for this item.